Quantitative effects of sodium–glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
The aim of the present study is to investigate the quantitative effects of sodium–glucose cotransporter-2 (SGLT-2) inhibitors on the quality of life in heart failure (HF) patients. A total of 14,674 HF patients from two dapagliflozin and three empagliflozin studies is included for analysis via the n...
Main Authors: | Dong-Dong Wang, Cun Zhang, Ping Zhu, Su-Mei He, Xiao Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.910858/full |
Similar Items
-
Exposure–Response Analysis of the Sodium–Glucose Cotransporter-2 Inhibitors Dapagliflozin and Empagliflozin on Kidney Hemodynamics in Patients with Type 2 Diabetes
by: Sjoukje van der Hoek, et al.
Published: (2023-04-01) -
Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01) -
Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01) -
Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023-08-01) -
The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022-11-01)